Mutual of America Capital Management LLC Buys 5,204 Shares of Blueprint Medicines Co. (NASDAQ:BPMC)

Mutual of America Capital Management LLC increased its position in shares of Blueprint Medicines Co. (NASDAQ:BPMC) by 16.6% during the 4th quarter, Holdings Channel reports. The firm owned 36,602 shares of the biotechnology company’s stock after acquiring an additional 5,204 shares during the period. Mutual of America Capital Management LLC’s holdings in Blueprint Medicines were worth $3,376,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of BPMC. American Century Companies Inc. grew its stake in Blueprint Medicines by 5.2% during the third quarter. American Century Companies Inc. now owns 670,972 shares of the biotechnology company’s stock valued at $33,696,000 after acquiring an additional 33,243 shares in the last quarter. Diversified Trust Co grew its stake in shares of Blueprint Medicines by 2.9% in the 3rd quarter. Diversified Trust Co now owns 11,219 shares of the biotechnology company’s stock worth $563,000 after buying an additional 318 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its stake in shares of Blueprint Medicines by 95.5% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,550 shares of the biotechnology company’s stock worth $78,000 after buying an additional 757 shares in the last quarter. Rafferty Asset Management LLC grew its stake in shares of Blueprint Medicines by 17.4% in the 3rd quarter. Rafferty Asset Management LLC now owns 166,690 shares of the biotechnology company’s stock worth $8,371,000 after buying an additional 24,693 shares in the last quarter. Finally, Vanguard Group Inc. boosted its stake in shares of Blueprint Medicines by 0.6% during the 3rd quarter. Vanguard Group Inc. now owns 5,967,143 shares of the biotechnology company’s stock worth $299,670,000 after purchasing an additional 37,716 shares during the period.

Blueprint Medicines Trading Up 2.7 %

Shares of BPMC opened at $88.38 on Thursday. Blueprint Medicines Co. has a 1-year low of $43.89 and a 1-year high of $101.00. The company has a 50-day moving average of $89.22 and a 200 day moving average of $76.96. The firm has a market capitalization of $5.41 billion, a price-to-earnings ratio of -10.57 and a beta of 0.63. The company has a debt-to-equity ratio of 1.60, a current ratio of 3.76 and a quick ratio of 3.66.

Blueprint Medicines (NASDAQ:BPMC) last posted its quarterly earnings results on Thursday, February 15th. The biotechnology company reported ($1.82) EPS for the quarter, beating the consensus estimate of ($2.04) by $0.22. Blueprint Medicines had a negative net margin of 203.30% and a negative return on equity of 191.56%. The business had revenue of $71.96 million during the quarter, compared to analyst estimates of $67.34 million. During the same quarter in the previous year, the business posted ($2.65) EPS. The company’s quarterly revenue was up 85.5% compared to the same quarter last year. On average, research analysts expect that Blueprint Medicines Co. will post -5.42 EPS for the current year.

Insider Activity

In other news, EVP Tracey L. Mccain sold 5,194 shares of the business’s stock in a transaction dated Thursday, March 7th. The shares were sold at an average price of $90.69, for a total value of $471,043.86. Following the completion of the sale, the executive vice president now owns 60,498 shares in the company, valued at approximately $5,486,563.62. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other news, Director Jeffrey W. Albers sold 25,000 shares of Blueprint Medicines stock in a transaction that occurred on Thursday, January 25th. The shares were sold at an average price of $81.91, for a total value of $2,047,750.00. Following the transaction, the director now owns 176,050 shares of the company’s stock, valued at approximately $14,420,255.50. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Tracey L. Mccain sold 5,194 shares of Blueprint Medicines stock in a transaction that occurred on Thursday, March 7th. The stock was sold at an average price of $90.69, for a total transaction of $471,043.86. Following the completion of the transaction, the executive vice president now directly owns 60,498 shares in the company, valued at approximately $5,486,563.62. The disclosure for this sale can be found here. In the last quarter, insiders sold 117,289 shares of company stock worth $10,361,913. 3.88% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

BPMC has been the subject of a number of recent analyst reports. Needham & Company LLC reaffirmed a “buy” rating and set a $97.00 price target on shares of Blueprint Medicines in a research note on Monday, February 26th. Stifel Nicolaus lifted their price target on shares of Blueprint Medicines from $95.00 to $97.00 and gave the stock a “buy” rating in a research note on Tuesday, January 9th. JMP Securities reaffirmed a “market outperform” rating and set a $114.00 price target on shares of Blueprint Medicines in a research note on Wednesday, April 10th. Wedbush reaffirmed an “outperform” rating and set a $97.00 price target on shares of Blueprint Medicines in a research note on Monday, February 5th. Finally, Raymond James lifted their price target on shares of Blueprint Medicines from $85.00 to $100.00 and gave the stock a “strong-buy” rating in a research note on Friday, December 22nd. Four investment analysts have rated the stock with a sell rating, two have assigned a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Blueprint Medicines presently has a consensus rating of “Hold” and an average target price of $85.43.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.